Akero Therapeutics is making strong progress in developing a treatment for NASH, an area of high unmet medical need. The company’s lead product candidate has
Biotech stocks have been consolidating recently but may be ready to rally higher due to factors such as a declining 10-year yield and growing M&A
The collapse of Silicon Valley Bank led to a market-wide selloff and caused significant volatility in biotech and technology stocks. Regulators are expected to take
Healthcare significantly outperformed the broader market last year, after two years of underperforming the S&P 500. When the end to restrictive policy is in sight,
Federal Reserve interest rate policy to again remain the market focus this year and create a chaotic first half. Biotechs should be favorably positioned relative
Biotechs are relatively better positioned in this fourth quarter compared to the broader market. The path of interest rates is clearer for 2022 and the
Healthcare Remains Steady As Market Approaches A Key Level The market is approaching a key technical level. Healthcare has relatively outperformed the market and has
Biotechs have sold off this year along with the broader market. Declines have been more pronounced than prior pullbacks. However, healthcare continues to outperform. Federal